Favipiravir Experience in Covid-19 Positive Myasthenia Gravis Patients.

Abstract

Myasthenia gravis (MG) is a disease that occurs as a result of an immunological attack against various proteins in the postsynaptic membrane, especially the postsynaptic acetylcholine receptors at the neuromuscular junction. Coronavirus disease (COVID-19), caused by the new virus severe acute respiratory syndrome coronavirus 2, became a worldwide pandemic. Although there is no definitive treatment for the disease as of yet, agents such as chloroquine, hydroxychloroquine, lopinavir, ritonavir, favipiravir, and remdesivir are used in many countries based on in vitro or observational studies. Considering that certain drugs can cause myasthenic exacerbation in patients with MG, the consequences of using drugs such as favipiravir in these patients are unknown. We aim to share our experience using favipiravir in 2 patients previously diagnosed with MG who tested positive for COVID-19.